Follicular lymphoma grade IIIb, lymph nodes of multiple sites
ICD-10 C82.48 is a billable code used to indicate a diagnosis of follicular lymphoma grade iiib, lymph nodes of multiple sites.
Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. Grade IIIb indicates a more aggressive form of the disease, where more than 50% of the neoplastic cells are large cells, which can lead to a more rapid progression and poorer prognosis compared to lower grades. This specific code, C82.48, is used when the lymphoma is present in lymph nodes at multiple sites, indicating systemic involvement. Patients may present with B-symptoms, which include fever, night sweats, and weight loss, and may require staging through imaging studies such as PET scans or CT scans to assess the extent of the disease. Treatment protocols often involve chemotherapy regimens, immunotherapy, or targeted therapies, and may include the use of monoclonal antibodies like rituximab. The management of follicular lymphoma is complex and requires a multidisciplinary approach, including oncologists, hematologists, and radiologists, to ensure optimal patient outcomes.
Comprehensive documentation of diagnosis, staging, treatment plans, and follow-up care.
Patients presenting with lymphadenopathy, B-symptoms, or those undergoing chemotherapy.
Ensure accurate grading and staging are documented to support the coding of C82.48.
Detailed imaging reports that specify the number and locations of affected lymph nodes.
Imaging studies performed for staging or monitoring treatment response.
Radiology reports must clearly indicate the extent of lymph node involvement to support coding.
Used when administering chemotherapy for follicular lymphoma grade IIIb.
Document the specific chemotherapy regimen and patient response.
Oncology specialists must ensure accurate coding of chemotherapy administration.
Key symptoms include lymphadenopathy, B-symptoms such as fever, night sweats, and weight loss, and fatigue. These symptoms can indicate disease progression and influence treatment decisions.
